#Denmark #Roche Diagnostics #Nordic Bioscience #PRO-C3 #Herlev

Nordic Bioscience Introduces PRO-C3 Test with Roche Diagnostics

In an exciting development for the medical community, Nordic Bioscience has launched its innovative PRO-C3 test in collaboration with Roche Diagnostics, now accessible on their cobas analyzers. This announcement marks a significant advancement in the field of liver health assessment, leveraging the Elecsys® PRO-C3 methodology.

Understanding the PRO-C3 Test

The Roche Elecsys® PRO-C3 test utilizes a unique formula called ADAPT, which integrates age, diabetes status, PRO-C3 levels, and platelet counts to evaluate the severity of liver fibrosis. Given that liver-related diseases are responsible for approximately one in every 25 deaths globally, this test plays a critical role in early detection and management, potentially saving countless lives.

The PRO-C3 biomarker has undergone extensive validation within Nordic Bioscience’s CAP-CLIA certified laboratory located in Denmark. This validation ensures that the technology adheres to rigorous quality standards, further highlighting Nordic Bioscience’s commitment to enhancing patient health through precision medicine.

Quality Backed by Research and Expertise

Over the past decade, Nordic Bioscience’s team of scientists has contributed to the academic community by publishing over 250 scientific papers focused on PRO-C3 and related fibrotic diseases. This extensive portfolio of research positions the company as a leader in this critical area of study. The PRO-C3 test is not only pioneering the way for liver assessment but is also the first biomarker from Nordic Bioscience’s fibrosis panel to receive CE approval.

Given that 40% of deaths in the Western world are associated with alterations in organ function, particularly the liver, the necessity for tools to quantify this condition cannot be overstated. The Elecsys PRO-C3 test epitomizes cutting-edge clinical chemistry, providing healthcare professionals with the precise data needed for effective intervention.

A Step towards Global Accessibility

Morten Karsdal, CEO of Nordic Bioscience, expressed pride in this collaborative milestone, stating, “The Elecsys PRO-C3 test is the first test launched from the collaboration between Nordic Bioscience and Roche Diagnostics. We are proud that our technology becomes globally available to make a difference for patients.” This partnership not only amplifies the reach of the PRO-C3 test but also caters to a broader audience in need of accurate and timely liver health assessments.

Conclusion

As Nordic Bioscience continues to expand its reach and influence, the introduction of the PRO-C3 test signifies a robust step forward in the field of biomarkers for liver disease. For more information on PRO-C3, you can visit their official page at Nordic Bioscience. This striking advancement in test availability represents a beacon of hope for patients and healthcare providers alike, emphasizing the role of precision medicine in modern diagnostics.

For inquiries related to products, please visit the contact page.